



DRUG DISCOVERY

Innovations in Epigenetics

Advances in Technologies, Diagnostics & Therapeutics

By Dr Cheryl L Barton

Dr Cheryl L Barton

Dr Cheryl L Barton is an independent consultant with over 16 years research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer's disease to schizophrenia, Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst. At ABN Amro NV she was lead analyst on several pan-European companies, and assessed the potential impact of new drug development on European Stocks.

In 2002, Dr Barton founded a consulting business, Pharmavision, to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research reports combine independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.

Copyright © 2009 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Innovations in Epigenetics

Executive summary	10	
Introduction	10	
Application in R&D & technological advances	10	
Exploring new therapeutic targets	11	
Epigenetic market, leading companies & pharmaceutical strategies	12	
The future of epigenetics	13	
Chapter 1	Introduction	16
What is epigenetics?		17
Epigenetics and phenotypes		19
Epigenetics a new biological paradigm		19
Epigenetics, genetics, genomics & pharmacogenomics		20
Molecular mechanisms associated with epigenetics		22
DNA methylation		22
Histone modifications		23
Nucleosome remodelling		23
Non-coding RNA		24
X chromosome inactivation		24
Gene imprinting		24
RNA interference		24
Epigenetic basis of disease		25
Epigenetic syndromes		25
Angelmann syndrome		25
Beckwith-Wiedemann syndrome		26
Prader-Willi syndrome		26
Why is epigenetics of interest to the pharmaceutical industry?		27
Biomarker discovery & diagnostics		28
Novel small molecule epigenetic therapeutics		28
Novel antisense therapeutics		28
Stem cells & regenerative medicines		29
Conclusions		29

Chapter 2 Application in R&D & technological advances 32

The application of epigenetics in drug R&D	33
DNA methylation biomarkers	34
Histone modification biomarkers	35
Technological advances in epigenetics	35
Chromatin immunoprecipitation	36
DNA methylation technologies	38
Non-coding RNA technologies	43
Bioinformatic modeling	43
Conclusions	44

Chapter 3 Exploring new therapeutic targets 48

Potential new therapeutic targets	49
Epigenetics in cancer	50
DNA methyltransferase & DNMT inhibitors	52
Case study: Vidaza (Celgene Corporation) & Dacogen (Eisai /J&J)	53
Case study: Zebularine a research tool	56
Histone acetylase (HAT) and histone deacetylase (HDAC)	59
Case study: Zolanza (Merck & Co.)	61
Case study: MGCD0103 (MethylGene/Taiho Pharmaceutical)	62
Case study: PCI-24781 (Pharmacyclics/Servier)	63
Histone demethylases and histone methyltransferases	65
Case study: PG11144 & PG11047 (Progen Pharmaceuticals)	66
Potential epigenetic based diagnostics	67
Diagnostic DNA methylation cancer biomarkers	67
Case study: Epi <i>pro</i> Colon (Epigenomics AG)	69
The next generation of epigenetic cancer biomarkers	71
Epigenetics in neurological disorders	72
Case study: EVP-0334 (EnVivo Pharmaceuticals)	73
Epigenetics in infectious diseases	75
Case study: MGCD290 (MethylGene)	75
Case study: siRNA targeting HIV-1 (Kevin Morris, Scripps, La Jolla)	76
Epigenetics in metabolic disorders	78
Epigenetics in cardiovascular disease	81
Epigenetics in ocular disorders	83
Case study: Kinase inhibitors (Otsuka Pharmaceutical/MethylGene)	84
Case study: Kinase inhibitors/S-adenosyl methionine (SAM) (Epizyme).	85
Conclusions	86

Chapter 4 Epigenetic market, leading companies & pharmaceutical strategies 90

Epigenetic market	91
Epigenetic therapeutic revenues: Now and the future	92
Leading epigenetic companies	93
4SC AG, Planegg-Martinsried, Germany	94
Celgene Corporation, Summit, New Jersey	95
Curis Inc, Cambridge, MA	96
Chroma Therapeutics Ltd, Oxon, UK	98
Constellation Pharmaceuticals, Cambridge, MA	99
EnVivo Pharmaceuticals, Watertown, MA	100
EpiTherapeutics Aps, Copenhagen, Denmark	101
Epizyme, Cambridge, MA	101
Gloucester Pharmaceuticals, Cambridge, MA	103
MethylGene, Inc. Montreal, Québec	104
Pharmacyclics, Sunnyvale, CA	106
Progen Pharmaceuticals, Brisbane, Australia	107
Repligen Corporation, Waltham, MA	109
SuperGen, Dublin, CA	110
Syndax Pharmaceuticals, Waltham, MA	112
TopoTarget, Copenhagen, Denmark	113
Summary of epigenetic-based companies	115
Recent alliances, mergers & acquisitions in epigenetics	115
Pharmaceutical strategies in epigenetics	118
GlaxoSmithKline, Middlesex, UK	118
Novartis, Basel, Switzerland	119
Merck & Co., Whitehouse, NJ	121
Eisai Corporation of North America, NJ	122
Takeda, Osaka, Japan	123
Overall conclusions	123

Chapter 5 The future of epigenetics 126

The future of epigenetics	127
Epigenetic consortia; unraveling the human epigenome	128
NIH's Roadmap Epigenomics Program initiative	128
European Epigenome Network of Excellence	130
Human Epigenome Consortium	130
KOLs in epigenetics	131
John Mattick, Institute for Molecular Bioscience, University of Queensland, Australia	132
Overview	132
Technology	133

Applications	133
Future	134
Kevin Morris, Scripps Institute, La Jolla, CA	134
Overview	134
Technology	135
Applications	135
Future	136
Monika Lachner, Max-Planck Institute of Immunobiology, Department of Epigenetics, Freiburg, Germany	136
Overview	136
Technology	136
Applications	137
Future	137
Johnathan Whetstone, Department of Medicine, Massachusetts General Hospital Cancer Center	137
Overview	138
Technology	138
Applications	138
Future	139
Peter Fraser, Head, Senior Fellow of the Medical Research Council, UK, The Babraham Institute, Cambridge	139
Overview	139
Technology	140
Applications	140
Future	141
Summary of KOLs commentary	141
Challenges	142
Fundamental research	142
Technological demands	142
Financial constraints	143
Intellectual property	144
Opportunities	144
Biomarker discovery & diagnostics	144
Therapeutic intervention	145
Regenerative medicines	145
Conclusions	146

Appendices 150

Glossary	150
Acknowledgements	156
Index	157
Index	157
Bibliography	159
Endnotes	165

List of Figures

Figure 1.1:	Timeline of epigenetics study	18
Figure 1.2:	Schematic of chromatin structure	22
Figure 1.3:	Schematic of epigenetic mechanisms associated with health and disease	23
Figure 1.4:	Epigenetic applications by the pharma industry	27
Figure 2.5:	Epigenetics in the drug discovery & development process	34
Figure 2.6:	Schematic of key technologies used in epigenetics	36
Figure 2.7:	Schematic of ChIP technology	37
Figure 2.8:	Epigenomics AG methylation specific PCR (MSP) methods	42
Figure 3.9:	DNA methylation targets for epigenetic cancer therapies	51
Figure 3.10:	Mechanism of action of HAT and HDAC	61
Figure 3.11:	Epi <i>proColon</i> high throughput colorectal epigenetic test	70
Figure 3.12:	Competitive pricing of Epi <i>proColon</i>	71
Figure 3.13:	EnVivo's HDAC project screening cascade	74
Figure 3.14:	Agouti mice and epigenetic manipulation	79
Figure 3.15:	Epizyme's rational design of small molecule HMT inhibitors	85
Figure 4.16:	Epigenetic therapies: product class and developmental phase	91
Figure 4.17:	Epigenetic therapies: therapy target and developmental phase	92
Figure 4.18:	CUDU-101 structure & design: combining multiple pharmacophores	97

List of Tables

Table 2.1:	DNA methylation PCR methods	40
Table 2.2:	Techniques to analyze DNA methylation	41
Table 3.3:	Examples of DNMT inhibitors: potential anticancer agents targeting epigenetic pathways	54
Table 3.4:	Examples of DNMT inhibitor research tools	55
Table 3.5:	HDAC inhibitors: potential anticancer agents targeting epigenetic pathways	57
Table 3.6:	Examples of HDAC inhibitor research tools	59
Table 3.7:	Histone modification and their effect on gene expression	60
Table 3.8:	Safety profiles of PCI-24781 rivals	64
Table 3.9:	DNA methylation sites associated with cancers	67
Table 3.10:	Validated and hypothetic miRNA targets for diabetes & obesity	81
Table 4.11:	Epigenetic therapeutic revenues (\$m), 2009-2020	93
Table 4.12:	Preliminary clinical data for Pharmacyclics PCI-24781	106
Table 4.13:	Recent alliances, acquisitions and mergers in the epigenetic arena	117
Table 5.14:	NIH Epigenetic Roadmap – funded epigenetic projects	129

